(UroToday.com) Advances in imaging have dramatically reshaped prostate cancer diagnosis, staging, and treatment. While multiparametric MRI (mpMRI) of the prostate has dramatically changed prostate cancer diagnosis, molecularly-targeted imaging has reshaped disease staging and detection of recurrent disease. Conventional imaging approaches using including computed tomography (CT) and bone scan have relatively limited sensitivity to detect disease recurrence following initial local therapy. The proPSMA trials, and other studies, have demonstrated that prostate-specific membrane antigen (PSMA) targeting PET radiopharmaceuticals detect disease not identified based on conventional imaging, with greater accuracy. In the Prostate, Testicular, Penile Poster session at the 2021 American Society of Clinical Oncology 2021 Annual Meeting, Dr. Michael Uy presented results of a multi-center registry assessing the ability of PSMA targeted PET/CT to detect sites of disease recurrence and affect patient management.